Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology Supplements
Published in: Clinical Research in Cardiology Supplements 1/2015

Open Access 01-04-2015

Editorial

Author: Prof. Dr. med. Dieter Horstkotte

Published in: Clinical Research in Cardiology Supplements | Special Issue 1/2015

Login to get access

Auszug

Atherosklerotisch bedingte kardiovaskuläre Erkrankungen führen in den Industriestaaten die Morbiditäts- und Mortalitätsstatistiken an. Insbesondere der koronaren Herzerkrankung und dem embolischen Schlaganfall kommen auch unter volkswirtschaftlichen Gesichtspunkten überragende Bedeutung zu. Entzündliche Gefäßwandprozesse stehen im Mittelpunkt von Pathogenese und Therapie der Atherosklerose. Lipoproteine wie z. B. oxidiertes low-density Lipoprotein (LDL), VLDL und das bisher weniger beachtete Lipoprotein-Antigen (Lp(a)) sind in besonderer Weise proinflammatorisch und damit atherogen. …
Metadata
Title
Editorial
Author
Prof. Dr. med. Dieter Horstkotte
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology Supplements / Issue Special Issue 1/2015
Print ISSN: 1861-0706
Electronic ISSN: 1861-0714
DOI
https://doi.org/10.1007/s11789-015-0076-y

Other articles of this Special Issue 1/2015

Clinical Research in Cardiology Supplements 1/2015 Go to the issue

OriginalPaper

Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias

OriginalPaper

Lipoprotein(a)—clinical aspects and future challenges

OriginalPaper

Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study

OriginalPaper

Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels

OriginalPaper

Extrakardiale Manifestation der Lipoprotein(a)-Erhöhung – Gehäuftes Auftreten von peripherer arterieller Verschlusskrankheit und Stenosen der Arteria carotis

OriginalPaper

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits